Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
doi: 10.3389/fendo.2023.1332114 Received 02 November 2023 Accepted 04 December 2023 Published 24 January 2024 Volume 14 - 2023 Edited by Stefano Zucchini, IRCCS University Hospital of Bologna Sant Orsola Polyclinic, Italy Reviewed by Cristina Partenope, Azienda Ospedaliero Universitaria Maggiore della Carit, Italy David Ingram, Childrens Mercy Kansas City, United States Updates Copyright 2024 Zaffanello, Pietrobelli, Cavarzere, Guzzo and Antoniazzi
Continued Healing: Further gut lining repair and long-term benefits can take several weeks to a few months, depending on the condition's severity
The model is transparent: $499 a year buys the membership, the testing, and the care, and peptide prescriptions are an add-on billed separately, not a bundled base fee